4.0.0 Terminology defined as part of the CDC Opioid Prescribing Guideline Implementation Guide

Note that the terminologies included in this implementation guide will need to be updated, because the ideal mechanism for distribution (as an expression) is not currently supported by the content logical definition constructs available in the FHIR ValueSet resource and all known implementations of it. Before use in a production environment, ensure you have the latest value sets based on the definitions for each value set (as defined in the inclusion/exclusion criteria for each one).

The following terminology artifacts have been defined for the CDC Opioid Prescribing Guidelines implementation guide:

4.1.0 CodeSystems

  • CDC Opioid Indicator
  • 4.2.0 ValueSets

  • Benzodiazepine Medications
  • Buprenorphine and Methadone Medications
  • CDC Malignant Cancer Conditions
  • Conditions Likely Terminal for Opioid Prescribing
  • Discharge to Hospice
  • End of Life Care
  • End of Life Conditions
  • Extended Release Opioids with Ambulatory Misuse Potential
  • Hospice Disposition
  • Hospice Observation Finding
  • Hospice Procedure/Request
  • Limited Life Expectancy Conditions - Enumerated
  • Limited Life Expectancy Conditions
  • Metastatic Cancer
  • Naloxone Medication
  • Non-opioid Illicit Drug Urine Screenings
  • Office Visit
  • Oncology Speciality Designation
  • Opioid Abuse Assessment
  • Opioid Analgesics with Ambulatory Abuse Potential
  • Opioid Counseling Procedure
  • Opioid Urine Screening
  • Opioid Abuse Assessment Procedure
  • Opioid Abuse Disorders
  • Action Indicators
  • Opioids Abused in Ambulatory Care
  • Opioid Medications
  • Pain Management Procedure
  • Pain Treatment Plans
  • PDMP Data Reviewed Findings
  • PCMP Review Procedures
  • Short-acting Opioiod Medications
  • Conditions Documenting Substance Abuse
  • Substance Abuse Counseling
  • Therapies Indicating End of Life Care